TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01564056
Drug: HORMONOTHERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
Study: NCT00130312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo gelcap in the morning and evening
Study: NCT03363022
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
Study: NCT05512468
Drug: carbon dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
Study: NCT03273257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given analogue to riociguat with matching tablets.
Study: NCT00864019
Drug: Zoloft® 100 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
Study: NCT01600222
Drug: LEO 90100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
Study: NCT03159897
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
Study: NCT00507728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth for 12 weeks.
Study: NCT00564486
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, every 6 hours for 24 hours (4 doses total)
Study: NCT00564486
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, every 4 hours for 24 hours (6 doses total)
Study: NCT00564486
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, every 6 hours for 24 hours (4 doses total)
Study: NCT00564486
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, every 4 hours for 24 hours (6 doses total)
Study: NCT02341573
Drug: experienced chinese herbal formulas
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
Study: NCT00003472
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT03126682
Drug: Wellbutrin SR 300Mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellbutrin SR 300Mg Extended-Release Tablet
Study: NCT02504060
Drug: Starch Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05801094
Drug: QL1604
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1604 3 mg/kg Q3W
Study: NCT03918980
Drug: LOU064
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOU064 will be administered as oral capsules in parts 1 to 6.
Study: NCT03918980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules will be administered in parts 1,2, 4 and 6.
Study: NCT01935557
Drug: Continuous heparin infusion
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
Study: NCT01935557
Drug: Intermittent heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
Study: NCT00798707
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Study: NCT03256526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg
Study: NCT04177173
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: improvement of disease activity
Study: NCT04177173
Drug: Methotrexate 10 mg
Normalized name: methotrexate 10 MG
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: improvement of disease activity
Study: NCT00864604
Drug: Nabumetone 750 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
Study: NCT00864604
Drug: Nabumetone 750 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Teva formulated products under fed conditions
Study: NCT02875340
Drug: VAL401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone formulated into a liquid lipid filled capsule
Study: NCT03467152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypromellose capsules.
Study: NCT04844710
Drug: standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard care only
Study: NCT02437227
Drug: CCT3833
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
Study: NCT02639026
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
Study: NCT01506986
Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three medications will be taken orally, twice daily, for seven days.
Study: NCT01506986
Drug: Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication to be taken orally, twice a day, for seven days.
Study: NCT02933229
Drug: H. pylori eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication.
Study: NCT00318942
Drug: Crystalloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
Study: NCT00318942
Drug: Colloids
Normalized name: Technetium (99mTc), particles and colloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
Study: NCT00318942
Drug: Crystalloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any crystalloids given for correction of hypovolemia during all ICU stay
Study: NCT00318942
Drug: Colloids
Normalized name: Technetium (99mTc), particles and colloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any colloids given for correction of hypovolemia during all ICU stay
Study: NCT02880085
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: local injection
Study: NCT00996008
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g (w/w) placebo cream applied to each target lesion twice daily
Study: NCT00034359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03993288
Drug: Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
Study: NCT00583128
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, sachet, 2 grams three times daily for 8 weeks
Study: NCT00583128
Drug: Celphere® CP-305
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, placebo, sachet, 2 grams three times daily for 8 weeks
Study: NCT02729545
Drug: Cyproterone acetate/ethinylestradiol (CPA/EE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
Study: NCT01889381
Drug: Bone marrow cell-based therapy & 1-drug immunosuppression.
Approvals — FDA: no, EMA: no, PMDA: no
Description: This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
Study: NCT04371874
Drug: Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
Study: NCT01389700
Drug: SAR279356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Study: NCT01389700
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Study: NCT04038255
Drug: Nicoderm C-Q Transdermal Product
Normalized name: Nicoderm C-Q Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks of nicotine replacement therapy patches
Study: NCT03978143
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Study: NCT03978143
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
Study: NCT03978143
Drug: Treatment G
Normalized name: VanaLice Lice Killing Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Study: NCT03978143
Drug: Treatment H
Normalized name: Walgreens Lice Treatment Homeopathic Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Study: NCT00732901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily days 1-28
Study: NCT05905614
Drug: SPH4336 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label SPH4336 Tablets ：Administered by oral
Study: NCT00853268
Drug: OxyContin® 40 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxyContin® 40 mg tablet, single dose with food
Study: NCT04305184
Drug: ASP0598
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.
Study: NCT03888131
Drug: CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
Study: NCT03888131
Drug: Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
Study: NCT02235415
Drug: Motens® (lacidipine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02623231
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Study: NCT04469465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02744742
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT04650984
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
Study: NCT00863239
Drug: Locteron™ (controlled-release interferon alpha 2b)
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
Study: NCT00863239
Drug: PEG-Intron™
Approvals — FDA: no, EMA: no, PMDA: no
Description: commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
Study: NCT03519152
Drug: low dose diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
Study: NCT03020966
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen, intravenous placebo
Study: NCT03020966
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen, oral placebo
Study: NCT02099331
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03107416
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
Study: NCT03652623
Drug: TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
Study: NCT02934568
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent LEE011 or in combination with other treatments
Study: NCT01733212
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
Study: NCT01768884
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01768884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03452475
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine tablets (20 mg/120 mg)
Study: NCT01847131
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
Study: NCT00331552
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00331552
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT02937584
Drug: GP MDI (PT001) 14.4 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium
Study: NCT02937584
Drug: FF MDI (PT005) 9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol Fumarate
Study: NCT02198001
Drug: tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10
Study: NCT00853216
Drug: Roxicodone™ tablet 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxicodone™ tablet 30 mg, single dose fasting
Study: NCT04511923
Drug: Nebulised heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
Study: NCT00382642
Drug: Placebo + Cognitive Behavioral Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 week outpatient trial
Study: NCT00934648
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg weekly
Study: NCT01482390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to mericitabine orally twice daily.
Study: NCT01101308
Drug: Reformulated OXY (Totowa) (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
Study: NCT01101308
Drug: Reformulated OXY (Wilson) (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
Study: NCT01695876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AMG 357 containing no active drug
Study: NCT00263393
Drug: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
Study: NCT04652414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a matching placebo to prednisone.
Study: NCT03406611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline for subcutaneous injection
Study: NCT03159611
Drug: Tenoten for children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
Study: NCT03159611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
Study: NCT01743001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macitentan-matching placebo oral tablet once daily
Study: NCT02162407
Drug: human soluble insulin
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
Study: NCT02470637
Drug: SAR439065
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:dry powder insulin~Route of administration: inhalation
Study: NCT02586506
Drug: Placebo ELLIPTA inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
Study: NCT02247648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients from control group received a shame tramadol pill on day one, two, and 3